✦ LIBER ✦

Opioid treatment programs in the Clinical Trials Network: Representativeness and buprenorphine adoption

✍ Scribed by Lori J. Ducharme; Paul M. Roman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Buprenorphine adoption in the National D

✍ Hannah K. Knudsen; Amanda J. Abraham; J. Aaron Johnson; Paul M. Roman 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Program and market characteristics assoc

✍ Christina Andrews; Peter Friedmann; Lan Jiang; Harold Pollack; Thomas D'Aunno 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Treatment programs in the National Drug

✍ Dennis McCarty; Bret Fuller; Lee Ann Kaskutas; William W. Wendt; Edward V. Nunes 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Innovation adoption in substance abuse t

✍ Lori J. Ducharme; Hannah K. Knudsen; Paul M. Roman; J. Aaron Johnson 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Pain and continued opioid use in individ

✍ Jennifer Sharpe Potter; Amit Chakrabarti; Catherine P. Domier; Maureen P. Hillho 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Predictors of buprenorphine–naloxone dos

✍ Amit Chakrabarti; George E. Woody; Margaret L. Griffin; Geetha Subramaniam; Roge 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 154 KB